Trials / Completed
CompletedNCT04662242
The Prognostic Impact of Selenium On Critical Surgical Patients
- Status
- Completed
- Phase
- Phase 4
- Study type
- Interventional
- Enrollment
- 36 (actual)
- Sponsor
- Chang Gung Memorial Hospital · Academic / Other
- Sex
- All
- Age
- 20 Years
- Healthy volunteers
- Not accepted
Summary
Selenium is an important trace element for human for its multiple roles such as the antioxidant activity. Previous evidences showed that critically ill patients may benefit from selenium supplement but the dose and results are controversial. Patients after operations for acute abdomen usually suffer from sepsis and stress. The aim of this study is to investigate the efficacy of selenium replacement in critical patients of acute abdomen, to see the impact on prognosis.
Detailed description
Acute abdomen is a common surgical emergency and is often the result of peritonitis due to an acute inflammatory process within abdominal cavity. Many of the patients with acute abdomen have severe sepsis and are critically ill that require an emergency surgery. The mortality rate of such patients are high because these patients usually have a profound pathophysiological dysregulation and multiple organ dysfunction. One of the mechanism of is the loss of anti-oxidative capacity of cells that fail to recover from ischemic-reperfusion injury. Selenium is an important cofactor that participate in the antioxidant activity of glutathione peroxidase reaction. There are evidences that critically ill patients may benefit from selenium supplement by better outcome and less mortality but the dose and results are still heterogenous and inconclusive. The aim of this study is to investigate the efficacy of selenium replacement in critical patients of acute abdomen, to see if there is a significant impact on prognosis, and to establish a clinical guide in the future.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | Selenium Supplement | Zelnite 400mcg/day in normal saline 100ml iv infusion for 7 days |
| DRUG | normal saline | normal saline 100ml iv infusion for 7 days |
Timeline
- Start date
- 2020-12-01
- Primary completion
- 2022-10-31
- Completion
- 2022-11-16
- First posted
- 2020-12-10
- Last updated
- 2023-02-10
Locations
1 site across 1 country: Taiwan
Source: ClinicalTrials.gov record NCT04662242. Inclusion in this directory is not an endorsement.